Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
REGULATORY MHLW Project Team Compiles Interim Proposal for Supporting Healthcare Startups
April 30, 2024
-
REGULATORY Govt’s Healthcare Advisors Call for Bolstering AMED Staff: 2025-2029 Strategy
April 30, 2024
-
ORGANIZATION New Task Force Discussing Steps to Stem Further Increase in Drug Lag/Loss: JPMA
April 30, 2024
-
BUSINESS PeptiDream to Start First-in-Human Trial for CAIX-Targeted Radiopeptide
April 30, 2024
-
ORGANIZATION JPMA Eager to Work with Regulators to Improve Guidance on Orphan Meds, PI Trials
April 30, 2024
-
BUSINESS Sanofi Seeks COPD Nod for Dupixent in Japan
April 30, 2024
-
BUSINESS Genmab Files ADC Tisotumab Vedotin for Cervical Cancer in Japan
April 30, 2024
-
REGULATORY Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
-
BUSINESS Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
April 26, 2024
-
BUSINESS Daiichi Sankyo Ups FY2025 Sales Goal to 2.1 Trillion Yen on Bullish Cancer Biz
April 26, 2024
-
REGULATORY MHLW’s Generic Industry Panel to Call for 5-Year Intensive Reform Period
April 26, 2024
-
REGULATORY Jaypirca, Prevymis, Relvar and More on MHLW Panel Agenda for May 9
April 26, 2024
-
BUSINESS Ono Ties Up with PRISM BioLab in Oncology Drug Discovery
April 26, 2024
-
BUSINESS Argenx Seeks Label Expansion for Vyvdura in Japan
April 26, 2024
-
BUSINESS Janssen Files Tremfya for Ulcerative Colitis in Japan
April 26, 2024
-
BUSINESS Janssen Primed to Join Japan Lung Cancer Market with Doublet Now under Review
April 26, 2024
-
BUSINESS Chugai’s Q1 Sales Drop 24% on End of Ronapreve Govt Purchase and Generic Competition
April 25, 2024
-
REGULATORY Regulation Panel’s Final Report Specifies Exemptions for All-Case PMS
April 25, 2024
-
REGULATORY Japan Plans More Prompt Drug Approvals from 2025, Within 3 Weeks of Panel Nod
April 25, 2024
-
BUSINESS Leqembi Gathers Pace with Sales Up 2.7-Fold in January-March: Eisai
April 25, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…